Corona will end in the nose, India launches first Covid nasal spray
Corona will end in the nose, India launches first Covid nasal spray

Mumbai: Mumbai-based pharma company Glenmark has launched nasal spray for the treatment of corona patients. It is designed in collaboration with the Canadian pharmaceutical company SaNOtize. This drug containing nitric oxide has been launched by a company in India under the name FabiSpray. This is India's first Covid nasal spray.

The company claims that if this spray is sprayed on the mucous of the nose, it physically and chemically creates barriers against the virus so that the infection does not reach the lungs. According to the company, the use of FabiSpray has led to a 94 per cent drop in viral load in 24 hours. In 48 hours, there has been a 99 per cent decrease. Dr Monica Tandon, Head and Senior Vice President, Clinical Development at Glenmark Company, has informed that the spray will be given only on prescription. That is, not everyone will be able to buy it.

He said that this spray is only for adult corona patients. It can only be purchased on medical advice. According to Dr Monica Tandon, the price of FabiSpray's 25 ml unit in India will be Rs 850. He has claimed that its price in India is much lower than in other countries. Dr Tandon said that from this week, these sprays will start getting sold at pharmacy shops.

High Court's big verdict in Lakhimpur violence case

Government issues new guidelines for international travellers, now these will be the rules for quarantine

Ind vs WI: Rohit Sharma admired Prasidh Krishna's bowling

Join NewsTrack Whatsapp group
Related News